PHOTO FILE: A picture of a cervical cancer anti-cervical vaccine box shows at a pharmacy in Strasbourg November 25, 2013. REUTERS / Vincent Kessler / File Photo
LONDON (Reuters) – 100,000 cancer cases in Britain could be prevented in the next 40 years by vaccination against human papilloma virus (HPV) that creates cervical cancers, mouth, anus and genitals, said UK health officials Tuesday.
Announcing the extension of a vaccination program to cover boys and girls, experts at Public Health England (PHE) said that the immunization plan would prevent around 64,000 cervical cancers and almost 50,000 cervical cancers by 2058.
This would be 50 years after the HPV vaccination program was introduced in Britain – started in girls in 2008 – when people who had been vaccinated as teenagers developing HPV-related cancer, PHE said in a statement.
HPV is a sexual transmission virus that is linked to more than 99% of cervical cancer, as well as 90% of cancer cancer, about 70% of vaginal cancer and vulvar and more than 60%. % d penile cancer.
PHE said from September this year that the shots will be offered to 12 and 13 year old boys in Britain as part of the government's health program.
Since UK girls started getting the HPV vaccine in 2008, studies have shown that 86% of people aged 16 to 21 years of age in England fell infections with some key types of the virus. A Scottish study also showed that the vaccine decreased by up to 71% on pre-cancerous cervical disease in women.
Robin Weiss, professor of viral oncology at University College London, said the extension of the HPV program should be “a buoyant situation”.
“The HPV vaccine has been very successful in protecting girls from cervical cancer as women,” he said. “It seems clear … that vaccinated boys will benefit from cancer from cancer, anus, and reduced risk of head and neck cancer.” T
Reporting by Kate Kelland; Edited by Andrew Cawthorne
(TTTranslate tags) US (t) HEALTH (t) HPV (t) BRITAIN (t) Child / Youth Issues (t) Vaccines (t) Health / Medicine (t) Western Europe (t) STD (t) Sexual Health (t) ) Life Sciences (t) Cancer (t) Europe (t) Men